\
&
Contact us
\
&
Contact us
Partnership website: https://www.effra.eu/made-in-europe-state-play
Made in Europe is a Horizon Europe co-programmed public-private partnership running for 7 years with a budget of €1.8 billion in total. The European Factories of the Future Research Association (EFFRA) represents the private side in the partnership. Made in Europe is successor to the Factories of the Future Partnership which has been run under the Horizon 2020 programme.
Made in Europe seeks to increase the number and attractiveness of jobs in manufacturing, while securing the environmental, economic and social sustainability for future generations in Europe. The Partnership will contribute to a competitive, green, digital, resilient and human-centric manufacturing industry in Europe. It will be at the centre of a twin ecological and digital transition, being both a driver and subject to these changes. The 2030 vision for the partnership is to reinforce the global position Europe’s manufacturing industry in terms of competitiveness, productivity, and technology leadership.
Contact
Partners: EFFRA – European Factories of the Future Research Association Info@effra.eu
About EFFRA
The European Factories of the Future Research Association (EFFRA) is a non-for-profit, industry-driven association promoting the development of new and innovative production technologies.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
